Bruker downgraded to Neutral from Buy at Citi

Citi analyst Patrick Donnelly downgraded Bruker (BRKR) to Neutral from Buy with a price target of $40, down from $50. The company’s exposure to the U.S. academic and government market may lead to order volatility which may linger into 2026, the analyst tells investors in a research note. The firm says that even if the National Institutes of Health budget cut comes in lighter than expected, academic and research institutions will remain more cautious on spending. Citi is more cautious on forward years than the recent share price decline suggests.